August 30, 2024 — Scientists have a pretty good handle on how to predict a person’s risk of diabetes and how to diagnose it. The gold standard is a glucose tolerance test. How does your body handle glucose? But diabetes is just one dimension of dietary disease risk and nutrition scientists are hungry for a better way to predict […]
August 28, 2024 — Type 2 diabetes prevalence is up and the Lancet Regional Health has a simple way to reduce it. Daniel Windred and colleagues write: “Advising people to turn off their lights at night, or use lights that reduce the circadian impact (dim and “warm” light), is a simple, cost-effective, and easily-implementable recommendation that may promote cardiometabolic […]
August 22, 2024 — From time to time, nutritional epidemiologists take themselves entirely too seriously. This week is one of those times. Health reporting is full of warnings that your lunch sandwich might give you type 2 diabetes. The senior author of the paper in Lancet Diabetes and Endocrinology causing this stir, Professor Nita Forouhi, expresses no caution about […]
August 21, 2024 — Yesterday, Eli Lilly and Company announced an impressive topline number from the results of a three-year study of tirzepatide in adults with obesity or overweight and prediabetes. That number was 94% prevention of progression from prediabetes to diabetes with tirzepatide. No, it was not 100%. But this is awfully close. Historical Context We will have to […]
August 10, 2024 — This is an impressive sales push. A diet of soups and shakes offers a brilliant path to weight loss, changing the lives of people with obesity and diabetes. So says the director of the NHS Type 2 Diabetes Path to Remission program, Clare Hambling: “It’s brilliant that these findings show a large number of those […]
August 1, 2024 — On the theme of “Is there anything GLP-1s can’t do?” a new randomized controlled trial is coming at us from the Alzheimer’s Association International Conference. It showed promising signs that a GLP-1, liraglutide, might slow the progression of Alzheimer’s disease. Liraglutide is used under the brand name Victoza to treat type 2 diabetes. At higher […]
July 31, 2024 — A fascinating new study in Annals of Internal Medicine asks an important question. When people receive semaglutide for type 2 diabetes, are they less likely to smoke? This is not such a random question. In fact, clinicians are reporting striking reductions in addictive behaviors by people receiving it for obesity. So William Wang and colleagues […]
July 15, 2024 — What should we take away from yet another suggestion that semaglutide might cut the risk of dementia? An Unexpected Finding This latest hint was a surprise. It comes from research that aimed to measure the risk of neurological and psychiatric problems associated with taking semaglutide for type 2 diabetes. Riccardo De Giorgi and colleagues were […]
July 7, 2024 — Letting go is hard. But there is a bright line between persistence and stubbornness. Persistence is absolutely necessary to advance a cause. But persistence gives way to stubbornness when facts line up to define serious limitations and people press on with a futile effort. Such is the case with the DiRECT obsession for “curing” type […]
March 3, 2024 — Five years ago, Danone asked FDA if it would be OK to say eating yogurt might prevent type 2 diabetes. Or to be precise, “eating yogurt regularly may reduce the risk of type 2 diabetes.” Friday, FDA told Danone, yep, we’re cool with that. Or, in the language of the agency: “FDA concludes that the […]
